Related references
Note: Only part of the references are listed.A role for JAK2 mutations in myeloproliferative diseases
Kelly J. Morgani et al.
ANNUAL REVIEW OF MEDICINE (2008)
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
C. Walz et al.
LEUKEMIA (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Comparative evaluation of three JAK2V617F mutation detection methods
Christine Frantz et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Consultations in molecular diagnostics - Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders
Qiaofang Chen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
Nicolaus Kroeger et al.
BLOOD (2007)
JAK2(V617F): prevalence in a large Chinese hospital population
Xuesong Xu et al.
BLOOD (2007)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
AV Jones et al.
BLOOD (2006)
Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis
G Murugesan et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
C James et al.
LEUKEMIA (2006)
The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors
P. Sidon et al.
LEUKEMIA (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
RL Levine et al.
BLOOD (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes
DP Steensma et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Mutation studies in CD3(+), CD19(+) and CD34(+) cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes
TL Lasho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99
P Johansson et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation
K Lindauer et al.
PROTEIN ENGINEERING (2001)
Share Paper
